Results 51 to 60 of about 1,341 (183)

Promising antimycotics for the treatment of invasive infections [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj   +1 more source

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Clinical and Translational Science, 2022
Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of
Kenan Gu, Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang, Taylor Sandison, Shawn Flanagan   +6 more
doaj   +1 more source

Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial [PDF]

, 2021
BackgroundRezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS ...
Pappas, Andes, Kullberg, Cornely, Zhao, Grau, Howard, Bader, Lakota, Shields, Sandison, Lepak, Hager, Lepak, Miesel, Flanagan, Pappas, Wiederhold, Gangneux, Safdar, Safdar, Betts, Yamazaki, Reboli, Jullien, Petraitiene, Zhao, Maseda, Wasmann   +28 more
core   +1 more source

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program

Open Forum Infectious Diseases, 2023
Abstract Background Rezafungin (RZF) is a new echinocandin (ECH) approved by the US FDA to treat candidemia and invasive candidiasis (IC). Fluconazole (FLC) resistance (R) is a raising concern to treat IC, and ECHs are often used as first-line therapy.
Carvalhaes, Cecilia G, Rhomberg, Paul, Klauer, Abby, Castanheira, Mariana   +3 more
openaire   +1 more source

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections

Antimicrobial Agents and Chemotherapy, 2021
Rezafungin is a novel antifungal agent of the echinocandin class with potent activity against species ofCandidaandAspergillus, including subsets of resistant strains, andPneumocystis jirovecii. The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the disposition of rezafungin in plasma following ...
Christopher M. Rubino, Shawn Flanagan
openaire   +2 more sources

Emerging and Future Strategies in the Management of Recalcitrant Candida auris [PDF]

, 2022
Candida auris is an emerging, multi drug resistant fungal pathogen that has caused infectious outbreaks in over 45 countries since its first isolation over a decade ago, leading to in-hospital crude mortality rates as high as 72%.
Bandara, Nihal, Samaranayake, Lakshman
core   +3 more sources

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)

Open Forum Infectious Diseases, 2023
Abstract Background Fluconazole (FLC) resistance (R) is common in C. glabrata (CGLA). Echinocandins (ECHs) are often used as first-line therapy. R to ECHs has been associated with FKS1 and FKS2 gene alterations.
Carvalhaes, Cecilia G, Rhomberg, Paul, Klauer, Abby, Deshpande, Lalitagauri M, Castanheira, Mariana   +4 more
openaire   +1 more source

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

Microorganisms, 2021
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates ...
Renátó Kovács, Zoltán Tóth, Jeffrey B. Locke, Lajos Forgács, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, László Majoros   +7 more
doaj   +1 more source

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Journal of Fungi, 2020
Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth, Lajos Forgács, Tamás Kardos, Renátó Kovács, Jeffrey B. Locke, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, Awid Adnan, László Majoros   +9 more
doaj   +1 more source

Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris [PDF]

, 2019
The enigmatic yeast Candida auris has emerged over the last decade and rapidly penetrated our consciousness. The global threat from this multidrug-resistant yeast has generated a call to arms from within the medical mycology community.
Kean, Ryan, Ramage, Gordon
core   +2 more sources